Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein-Reference-Cited by-同舟云学术

Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein

Published:2014-10-03 Issue:11 Volume:5 Page:1202-1206
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Cumaraswamy Abbarna A.¹,Lewis Andrew M.¹,Geletu Mulu¹,Todic Aleksandra¹,Diaz Diego B.¹,Cheng Xin Ran²,Brown Carla E.¹,Laister Rob C.³,Muench David⁴,Kerman Kagan²,Grimes H. Leighton⁴,Minden Mark D.³,Gunning Patrick T.¹

Affiliation:

1. Department of Chemistry, University of Toronto Mississauga, Mississauga, Ontario L5L 1C6, Canada

2. Department of Physical & Environmental Sciences, University of Toronto at Scarborough, Toronto, Ontario M1C 1A4, Canada

3. Princess Margaret Cancer Centre, Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada

4. Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 45229, United States

Funder

Princess Margaret Foundation

Canada Research Chairs

National Institutes of Health

Natural Sciences and Engineering Research Council of Canada

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml500165r

Reference22 articles.

1. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

2. Cardiovascular toxicity of tyrosine kinase inhibitors

3. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

4. Acquired resistance to tyrosine kinase inhibitors during cancer therapy

5. Mechanisms of drug resistance in kinases

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia;Journal of Medicinal Chemistry;2023-02-03

2. Stafiba: A STAT5‐Selective Small‐Molecule Inhibitor;ChemBioChem;2022-11-24

3. STAT5 as a Key Protein of Erythropoietin Signalization;International Journal of Molecular Sciences;2021-07-01

4. Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential;ChemMedChem;2021-01-20

5. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo;Cancers;2020-11-18